1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • March 2021
  • 131 pages
  • ID: 6039474
  • Format: PDF
  • Mordor Intelligence LLP


Table of Contents

Search Inside

The global viral vector and plasmid DNA manufacturing market was valued at USD 591.29 million in 2020, and it is expected to reach USD 2,244.29 million by 2026, registering a CAGR of 23.38 %, during the period of 2021-2026.

COVID-19 is expected to have a positive effect on the Viral Vector and Plasmid DNA Manufacturing Market. Several COVID-19 vaccine candidates that are entering clinical trials include viral vector vaccines. These vaccines are likely to be among the COVID-19 vaccines authorized for use across the world. Many of them have also received or are in the final stages of receiving approval. In January 2021, Johnson & Johnson announced favorable efficacy and safety data from its Phase 3 ENSEMBLE clinical trial using its AdVac vaccine platform for COVID-19. Its single-dose COVID-19 vaccine, currently under development, at its Janssen Pharmaceutical Companies, was found to have met all preconditions and targets. The AdVac viral vector technology could provide a potent and long-lasting humoral and cellular immune response to the body. Another viral vector-based vaccine, which has received several approvals is the Oxford-AstraZeneca COVID-19 vaccine. The vaccine was first discovered in November 2020 and has since then been mass-produced to vaccinate people. The COVID-19 viral vector vaccines under development across the world using non-replicating viral vectors. The immune response of these vaccines follow a similar pattern: it includes antibody-producing B cells, as well as T cells, which seek out and destroy infected cells in the body providing long-lasting immunity. Further research and increased investment in this field are expected to have a positive effect on vaccine development.

Demand for plasmid DNA is rising steeply because of a boom in gene therapy development. pDNA is a prerequisite for the production of AAV (adeno-associated virus), lentivirus, and other viral vector platforms. There is also an increase in several genetic disorders and numerous life-threatening disorders, especially heart diseases, AIDS, cystic fibrosis, and age-related disorders. For instance, According to the World Health Organization, an estimated 17.9 million people die due to cardiovascular diseases worldwide, each year. This represents 35% of global deaths. Gene therapy with viral vectors thus provides a complete cure to patients affected with genetic disorders and other life threateningdisorders, rather than ease symptoms with other therapeutic treatments. A number of clinical studies are being conducted on viral vectors and plasmid DNA manufacturing, emphasizing the potential of gene therapy, to address important medical needs. According to a research article published in 2019, ’Cancer DNA vaccines: current preclinical and clinical developments and future perspectives’, it was estimated that personalized DNA vaccines for the treatment of cancers are the future choice to provide the most appropriate combined therapy by analyzing single patient specificity and biomarkers that can predict the response to a specific agent.

Several players, including pharmaceutical companies, contract manufacturing organizations, research institutes, and non-profit organizations, are playing a critical role in the development and production of these vectors. In 2018, UniQure Biopharma BV sponsored for the trial of AMT-061 in severe or moderately severe Hemophilia B patients, and AMT-061 is a recombinant adeno-associated viral vector.

Moreover, factors, such as technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, are primarily driving the demand for viral vector and plasmid DNA manufacturing. However, high cost of gene therapies and challenges in viral vector manufacturing capacity are expected to obstruct the market growth.

Key Market Trends
Plasmid DNA Segment is Expected to Register Robust Growth.

Plasmid DNA plays a key role in healthcare, as it is used directly as a therapeutic agent in gene therapy or generation of vaccine antigens. Furthermore, plasmid DNA is used as a master-template product to support production of new and emerging biopharmaceutical products and processes including in-vitro protein production, RNA and cell therapies. The recent advances have led to the emergence of several other innovative viral/ non-viral gene delivery approaches that are being utilized for the development of various therapies that require gene modification

The demand and therapeutic applications for plasmid DNA have grown rapidly and have expanded. Plasmid DNA and viral vector-based cancer vaccines have several inherent features that make them promising cancer vaccine candidates. The plasmid DNA is also being used to deliver tumor-specific antigens to induce a tumor-specific immune response. Their applications in cancer have, in turn, helped in the growth of the market.

The increase in interest in this field can be understood by the rising number of mergers and acquisitions. For example, in July 2019, EQT VIII Fund announced that it had acquired a majority interest in Aldevron. Aldevron is one of the largest suppliers of GMP, GMP-SourceTM and Research Grade plasmid DNA. Its products are used in clinical, commercial, and research stage gene therapies, as well as in the manufacture of proteins, antibodies and mRNA.

Moreover, growing R&D on cancer research owing to the rising burden of the disease and the increasing demand for DNA therapeutics are expected to fuel the segment growth over the forecast period.

North America Dominates the Market in Terms of Revenue Generated

Currently, the North American viral vector and plasmid DNA manufacturing market is witnessing rapid growth in the market studied. Companies in the region are innovating new product approaches for viral vectors. For example, in April 2018, United States-based GE Healthcare created a ‘factory-in-a-box’ facility for the production of viral vector-based drugs, including viral vector vaccines, oncolytic viruses, and gene and cell therapies. Many companies are increasing their production facilities too. For example, in January 2020, Genopis Inc. announced that it will build a contract manufacturing business for plasmid DNA production in the United States with its South Korea-based partner Helixmith. In January 2021, United States-headquartered Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, announced that it had begun a multi-phase increase in its plasmid DNA services as a continuation of its gene therapy services’ expansion project for viral vectors and plasmid DNA.

Gene therapy in Canada is also rising rapidly which is used for the treatment of various diseases. For instance, Kymriah was the first gene therapy product approved in Canada for treating cancer in September 2018. Health Canada approved Novartis Kymriah for use in pediatric, young adult, and adult patients.

In February 2019, Health Canada also approved another gene therapy product called Yescarta and manufactured by Kite Pharmaceuticals for an aggressive kind of non-Hodgkins lymphoma. Viral vector design and manufacturing control are critically important for the overall product quality, safety, and efficiency in patients through concerns, such as replication competence, vector integration, and vector shedding. Furthermore, there is significant advancements in developing novel viral vectors and several researchers are focusing on substituting pathogenic genes with therapeutic DNA. In addition, nowadays non-pathogenic, replication-defective, and human-friendly viral vectors are being widely used in gene therapy clinical trials and as more research is expected to be conducted on viral vectors and plasmid DNA, these developments are expected to have a positive effect on market growth.

Competitive Landscape
The market studied is still in its infant stage. Hence, the increasing focus is mainly on the development of innovative products. Key market players include Cobra Biologics, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc, and Thermo Fisher Scientific among others.

Various strategies, such as research and development, mergers and acquisition, and product launch, are being adopted by domestic companies to strengthen their market position. In December 2020, CHA Biotech signed a lease agreement with Matica Bio, to construct a viral vector production facility in College Station, Texas. The construction of the 25,000 sq. ft facility started in Q4 2020, and it is expected to be dedicated to the production of viral vectors used in cell and gene therapies, vaccines, and oncolytic products. It is scheduled to open in Q3 2021.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Cell & Gene Therapy Manufacturing Services Market by Type, Indication, Application, End User - Global Forecast to 2026

  • $ 4950
  • July 2021
  • 285 pages

The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this ...

  • World
  • Europe
  • Gene Therapy
  • Industry analysis
  • Cancer Incidence
  • Pharmaceutical R&D Expenditure

Precision Medicine Market $ 4900 March 2021


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on